Royal London Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20.2M | Buy |
252,087
+3,549
| +1% | +$293K | 0.04% | 321 |
|
|
2025
Q4 | $21.2M | Sell |
248,538
-5,383
| -2% | -$442K | 0.04% | 311 |
|
|
2025
Q3 | $19.7M | Sell |
253,921
-4,926
| -2% | -$385K | 0.04% | 323 |
|
|
2025
Q2 | $20.2M | Sell |
258,847
-14,665
| -5% | -$1.09M | 0.05% | 318 |
|
|
2025
Q1 | $19.8M | Buy |
273,512
+22,307
| +9% | +$1.6M | 0.05% | 316 |
|
|
2024
Q4 | $18.6M | Buy |
251,205
+5,027
| +2% | +$352K | 0.05% | 314 |
|
|
2024
Q3 | $16.2M | Buy |
246,178
+6,539
| +3% | +$475K | 0.04% | 337 |
|
|
2024
Q2 | $22.1M | Buy |
239,639
+2,006
| +0.8% | +$178K | 0.06% | 260 |
|
|
2024
Q1 | $22.7M | Buy |
237,633
+5,296
| +2% | +$445K | 0.06% | 259 |
|
|
2023
Q4 | $17.7M | Sell |
232,337
-5,427
| -2% | -$378K | 0.05% | 279 |
|
|
2023
Q3 | $16.5M | Buy |
237,764
+8,775
| +4% | +$705K | 0.05% | 267 |
|
|
2023
Q2 | $21.6M | Buy |
228,989
+5,659
| +3% | +$492K | 0.07% | 219 |
|
|
2023
Q1 | $18.5M | Sell |
223,330
-575,184
| -72% | -$45.2M | 0.07% | 208 |
|
|
2022
Q4 | $59.6M | Buy |
798,514
+12,843
| +2% | +$990K | 0.27% | 76 |
|
|
2022
Q3 | $65M | Sell |
785,671
-29,182
| -4% | -$2.81M | 0.33% | 58 |
|
|
2022
Q2 | $77.5M | Buy |
814,853
+94,587
| +13% | +$9.79M | 0.36% | 59 |
|
|
2022
Q1 | $84.8M | Buy |
720,266
+9,570
| +1% | +$1.07M | 0.33% | 59 |
|
|
2021
Q4 | $92M | Sell |
710,696
-8,411
| -1% | -$981K | 0.34% | 58 |
|
|
2021
Q3 | $81.4M | Sell |
719,107
-7,756
| -1% | -$885K | 0.33% | 62 |
|
|
2021
Q2 | $75.3M | Sell |
726,863
-9,384
| -1% | -$885K | 0.31% | 66 |
|
|
2021
Q1 | $61.6M | Buy |
736,247
+6,965
| +1% | +$589K | 0.28% | 77 |
|
|
2020
Q4 | $66.5M | Buy |
+729,282
| New | +$60.5M | 0.35% | 64 |
|
|
2020
Q3 | – | Sell |
-436,005
| Closed | -$29.6M | – | 639 |
|
|
2020
Q2 | $29.6M | Sell |
436,005
-3,156
| -0.7% | -$224K | 0.21% | 106 |
|
|
2020
Q1 | $28.8M | Buy |
439,161
+56,307
| +15% | +$4.06M | 0.23% | 101 |
|
|
2019
Q4 | $29.7M | Buy |
382,854
+137,364
| +56% | +$10.7M | 0.21% | 113 |
|
|
2019
Q3 | $18M | Buy |
+245,490
| New | +$17.2M | 0.14% | 170 |
|
|
2019
Q2 | – | Sell |
-255,843
| Closed | -$16.3M | – | 605 |
|
|
2019
Q1 | $16.3M | Sell |
255,843
-16,458
| -6% | -$939K | 0.13% | 170 |
|
|
2018
Q4 | $13.7M | Buy |
272,301
+17,229
| +7% | +$872K | 0.12% | 182 |
|
|
2018
Q3 | $14.8M | Sell |
255,072
-4,902
| -2% | -$240K | 0.15% | 139 |
|
|
2018
Q2 | $12.6M | Buy |
+259,974
| New | +$12.1M | 0.13% | 182 |
|
|
2016
Q2 | $7.13M | Sell |
214,485
-13,702,656
| -98% | -$469M | 0.12% | 193 |
|
|
2016
Q1 | $53K | Buy |
13,917,141
+13,685,088
| +5,897% | +$378M | 0.08% | 291 |
|
|
2015
Q4 | $6.13M | Buy |
232,053
+2,559
| +1% | +$66.5K | 0.09% | 230 |
|
|
2015
Q3 | $5.44M | Buy |
+229,494
| New | +$5.54M | 0.09% | 245 |
|
|
2014
Q3 | – | Sell |
-152,352
| Closed | -$2.41M | – | 564 |
|
|
2014
Q2 | $2.41M | Sell |
152,352
-792
| -0.5% | -$10.7K | 0.06% | 348 |
|
|
2014
Q1 | $2.2M | Sell |
153,144
-6,042
| -4% | -$69.7K | 0.05% | 378 |
|
|
2013
Q4 | $1.82M | Sell |
159,186
-60
| -0% | -$676 | 0.05% | 420 |
|
|
2013
Q3 | $2.06M | Buy |
159,246
+2,292
| +1% | +$26.8K | 0.06% | 381 |
|
|
2013
Q2 | $1.75M | Buy |
+156,954
| New | +$1.86M | 0.05% | 401 |
|
Other funds holding EW
VCM
VPM
Royal London Asset Management's EW Position: Q1 2026 in Review
Royal London Asset Management increased its Edwards Lifesciences (EW) stake by 1.4% in Q1 2026, buying an estimated $293K and bringing the position to 252,087 shares worth $20.2M. The position accounts for 0.04% of the portfolio, ranked #321.
Royal London Asset Management first reported a position in EW in Q2 2013 and has held it in 39 quarters since. The position peaked at $92M in Q4 2021. 1,286 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Royal London Asset Management held 252,087 shares of Edwards Lifesciences worth $20.2M as of Q1 2026.
- Royal London Asset Management bought 3,549 Edwards Lifesciences shares in Q1 2026, an estimated $293K.
- Edwards Lifesciences made up 0.04% of Royal London Asset Management's portfolio in Q1 2026, its #321 holding.
- Royal London Asset Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 39 quarters since.
- Royal London Asset Management's Edwards Lifesciences position peaked at $92M in Q4 2021.
- 1,286 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Royal London Asset Management's 13F filing for Q1 2026, filed 1 May 2026.